🔎 Trials Near Me

Home › Burkitt Lymphoma

Burkitt Lymphoma clinical trials recruiting in the U.S.

63 studies for Burkitt Lymphoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT03223610

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06144606

A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia

RecruitingPhase 3
Ages 1 and older · All sexes · Updated Sep 17, 2026 · NCT07223021

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

RecruitingPhase 1/2
31 Days – 30 Years · All sexes · Updated Sep 14, 2026 · NCT04544592

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 25, 2026 · NCT05389423

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Aug 19, 2026 · NCT06137118

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

RecruitingPhase 1
Ages 18 to 81 · All sexes · Updated Aug 6, 2026 · NCT05990465

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

Blinatumomab Consolidation in Real World

RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07117136

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07069699

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.